Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy

International Journal of Oncology

Volumn 31, Issue 2, 2007, Pages 313-322

  Zembutsu, Hitoshi ^a   Yanada, Masamitsu ^b   Hishida, Asahi ^a   Katagiri, Toyomasa ^a   Tsuruo, Takashi ^c   Sugiura, Isamu ^d   Takeuchi, Jin ^e   Usui, Noriko ^f   Naoe, Tomoki ^b   Nakamura, Yusuke ^a   Ohno, Ryuzo ^g  

^a UNIVERSITY OF TOKYO   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Cancer Research Institute   (Japan)

^d TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^e NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acute lymphoblastic leukemia; BCR Abl; Imatinib; Microarray; Prediction; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GENOME; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; RISK;

ADULT; ANTINEOPLASTIC AGENTS; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RECURRENCE; RISK;

EID: 35148876162     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.2.313     Document Type: Article

References (51)

1. Faderl S, Kantarjian HM, Talpaz M and Estrov Z: Clinical significance of minimal residual disease in leukemia. Int J Oncol 17: 1277-1287, 2000.
2. Schlieben S, Borkhardt A, Reinisch I, et al: Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 10: 957-963, 1996.
3. Gokbuget N, Hoelzer D, Arnold R, et al: Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 14: 1307-1325, 2000.
4. Garcia-Manero G and Kantarjian HM: The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 14: 1381-1396, 2000.
5. Preti HA, O'Brien S, Giralt S, Beran M, Pierce S and Kantarjian HM: Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med 97: 60-65, 1994. (Pubitemid 24223635)
6. Thiebaut A, Vernant JP, Degos L, et al: Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 14: 1353-1366, 2000.
7. Larson RA: Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia group B. Hematol Oncol Clin North Am 14: 1367-1379, 2000.
8. Arico M, Valsecchi MG, Camitta B, et al: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342: 998-1006, 2000. (Pubitemid 30180646)
9. Forman SJ, O'Donnell MR, Nademanee AP, et al: Bone marrow transplantation for patients with Philadelphia chromosomepositive acute lymphoblastic leukemia. Blood 70: 587-588, 1987.
10. Radich JP: Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 15: 21-36, 2001. (Pubitemid 32201866)
11. Schrappe M, Arico M, Harbott J, et al: Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92: 2730-2741, 1998.
12. Snyder DS: Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant 6: 597-603, 2000.
13. Avivi I and Goldstone AH: Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplant 31: 623-632, 2003. (Pubitemid 36553471)
14. Barrett AJ, Horowitz MM, Ash RC, et al: Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 79: 3067-3070, 1992.
15. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B and Kuriyan J: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289: 1938-1942, 2000.
16. Mauro MJ, O'Dwyer M, Heinrich MC and Druker BJ: STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 20: 325-334, 2002. (Pubitemid 34032628)
17. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346: 645-652, 2002. (Pubitemid 34815868)
18. Ottmann OG, Druker BJ, Sawyers CL, et al: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100: 1965-1971, 2002.
19. Hochhaus A, Kreil S, Corbin AS, et al: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16: 2190-2196, 2002.
20. Thomas DA, Faderl S, Cortes J, et al: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103: 4396-4407, 2004. (Pubitemid 38745962)
21. Von Bubnoff N, Peschel C and Duyster J: Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 17: 829-838, 2003. (Pubitemid 36626307)
22. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004, 2003.
23. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038-1042, 2001.
24. De Labarthe A, Rousselot P, Huguet-Rigal F, et al: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia - results of the GRAAPH-2003 study. Blood 27: 22, 2006.
25. Towatari M, Yanada M, Usui N, et al: Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104: 3507-3512, 2004.
26. Wassmann B, Pfeifer H, Goekbuget N, et al: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 108: 1469-1477, 2006.
27. Yanada M, Takeuchi J, Sugiura I, et al: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24: 460-466, 2006.
28. Talpaz M, Shah NP, Kantarjian H, et al: Dasatinib in imatini-bresistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531-2541, 2006.
29. Kantarjian H, Giles F, Wunderle L, et al: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-2551, 2006. (Pubitemid 43882350)
30. Ono K, Tanaka T, Tsunoda T, et al: Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60: 5007-5011, 2000.
31. Okabe H, Satoh S, Kato T, et al: Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61: 2129-2137, 2001.
32. Zembutsu H, Ohnishi Y, Tsunoda T, et al: Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 62: 518-527, 2002.
33. Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537, 1999.
34. Takata R, Katagiri T, Kanehira M, et al: Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genomewide gene expression profiling. Clin Cancer Res 11: 2625-2636, 2005.
35. Hofmann WK, De Vos S, Elashoff D, et al: Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 359: 481-486, 2002.
36. Yang W, Lo CG, Dispenza T and Cerione RA: The Cdc42 target ACK2 directly interacts with clathrin and influences clathrin assembly. J Biol Chem 276: 17468-17473, 2001. (Pubitemid 37411562)
37. Teo M, Tan L, Lim L and Manser E: The tyrosine kinase ACK1 associates with clathrin-coated vesicles through a binding motif shared by arrestin and other adaptors. J Biol Chem 276: 18392-18398, 2001. (Pubitemid 37411413)
38. Ahmed I, Calle Y, Sayed MA, et al: Cdc42-dependent nuclear translocation of non-receptor tyrosine kinase, ACK. Biochem Biophys Res Commun 314: 571-579, 2004.
39. Meyerholz A, Hinrichsen L, Groos S, Esk PC, Brandes G and Ungewickell EJ: Effect of clathrin assembly lymphoid myeloid leukemia protein depletion on clathrin coat formation. Traffic 6: 1225-1234, 2005. (Pubitemid 41632272)
40. Kovar J, Valenta T and Stybrova H: Differing sensitivity of tumor cells to apoptosis induced by iron deprivation in vitro. In Vitro Cell Dev Biol Anim 37: 450-458, 2001.
41. Leardi A, Caraglia M, Selleri C, et al: Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells. Br J Haematol 102: 746-752, 1998. (Pubitemid 28387058)
42. Potaznik D, Groshen S, Miller D, et al: Association of serum iron, serum transferrin saturation, and serum ferritin with survival in acute lymphocytic leukemia. Am J Pediatr Hematol Oncol 9: 350-355, 1987. (Pubitemid 18009280)
43. Moura IC, Lepelletier Y, Arnulf B, et al: A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 103: 1838-1845, 2004.
44. Hutchinson E: Clinging on. Nat Rev Cancer 3: 717, 2003.
45. Irving JA, Minto L, Bailey S and Hall AG: Loss of heterozygosity and somatic mutations of the glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course. Cancer Res 65: 9712-9718, 2005. (Pubitemid 41541447)
46. Kirschner-Schwabe R, Lottaz C, Todling J, et al: Expression of late cell cycle genes and an increased proliferative capacity characterize very early relapse of childhood acute lymphoblastic leukemia. Clin Cancer Res 12: 4553-4561, 2006.
47. Matsunaga T, Takemoto N, Sato T, et al: Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9: 1158-1165, 2003.
48. Franco SJ and Huttenlocher A: Regulating cell migration: calpains make the cut. J Cell Sci 118: 3829-3838, 2005.
49. Yuan Y, Dopheide SM, Ivanidis C, Salem HH and Jackson SP: Calpain regulation of cytoskeletal signaling complexes in von Willebrand factor-stimulated platelets. Distinct roles for glycoprotein Ib-V-IX and glycoprotein IIb-IIIa (integrin alphaIIbbeta3) in von Willebrand factor-induced signal transduction. J Biol Chem 272: 21847-21854, 1997. (Pubitemid 27382801)
50. Yan B, Calderwood DA, Yaspan B and Ginsberg MH: Calpain cleavage promotes talin binding to the beta 3 integrin cytoplasmic domain. J Biol Chem 276: 28164-28170, 2001. (Pubitemid 37391519)
51. Ma XJ, Wang Z, Ryan PD, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616, 2004.